Dublin, 29 Nov. 2022 (GLOBE NEWSWIRE) — The “Home Self-Test Kits Market Distribution by Test Format Type, Biofluid Type Analyzed Therapeutic Area and Key Geographical Regions, Europe, Asia-Pacific, Africa and South America ): Industry Trends and Global Forecasts, 2022-2035” -report has been added to ResearchAndMarkets.com’s sacrifice.
This report contains an extensive study of the current market landscape and future potential related to the Home Self-Test Kits market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders involved in this field. The report contains, among other things:
Since the approval of the first over-the-counter test kits in early 1976, there has been a significant increase in the development initiatives focused on such products. In this context, it is worth emphasizing that more than 20 million home pregnancy test kits are sold annually in the US.
Companies have also developed at-home diagnostic kits for the detection and diagnosis of various diseases, such as human immunodeficiency virus (HIV) infection, diabetes, hepatitis C, colon cancer and COVID-19. Specifically, after the onset of COVID-19, there was an increase in demand for self-test kits.
In fact, in 2021, more than 100 home self-test kits have been approved by the USFDA for the diagnosis of COVID-19. The popularity of these kits can be attributed to the fact that they are more reliable, efficient, high-throughput, as well as compatible with a wide range of input samples, including blood, cells, tissues, plasma, saliva and microbes.
Given the extensive use of home test kits in the diagnosis of a host of disease indications, there has been a significant increase in investment in this domain. More than USD 2.2 billion has been invested in this domain by various government institutions in the US over the past five years.
Furthermore, the current market landscape is consolidated and mainly dominated by the kits being developed to detect pregnancies, monitor glucose and ovulation patterns. We believe that, with an increase in the number of point-of-care test kits being developed across various therapeutic areas, such as infectious diseases and celiac disease, and their subsequent commercialization, opportunities for self-test kit developers are likely to increase. in the foreseeable future.
Currently, efforts are also underway to connect home diagnostic tests with telemedicine; this is expected to enable a quick turnaround time. The continuous innovations in this market are expected to bring a positive revolution in the healthcare domain. Given the continuous efforts undertaken by industry players, the home self-test kits market is poised to witness healthy growth over the next decade.
One of the key objectives of the report was to estimate the current opportunity and future size of the home self-testing kits market. We have provided informed estimates on the likely evolution of the market in the short to medium term and long term, over the period 2022-2035.
The year-wise projections of the current and future opportunity are further segmented on the basis of [A] therapeutic area (fertility and reproductive health, metabolic disorders, infectious diseases and oncological disorders), [B] type of biofluid analyzed (blood, urine and stool), [C] type of test format (cassette, strip, stick and others), [D] key geographic regions (North America, Europe, Asia Pacific, Africa and South America). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures were obtained and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.
Key questions answered
- Who are the leading players involved in Home Self Test Kits manufacturing?
- What is the most common diagnostic test offered by home self-test kit manufacturers?
- What are the major regulatory frameworks for home self-test kits across different geographic regions?
- Which companies/institutes have received grants for the research and development of home self-test kits?
- What are the key factors affecting the price of home self-test kits?
- What is the likely valuation / net worth of companies involved in this domain?
- What is the current global demand for home self-test kits?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What is the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments?
Key topics covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Home Self-Test Kits: List of Developers
4.2.1. Analysis by year of establishment
4.2.2. Analysis by Company Size
4.2.3. Breakdown by location of headquarters
4.2.4. Breakdown by company size and location of headquarters
4.2.5. Breakdown by year of foundation, company size and location of headquarters
4.3. Home Self-Test Kits: Overall Market Landscape
4.3.1. Analysis by type of test procedure
4.3.2. Analysis by type of test format
4.3.3. Analysis by purpose of testing
4.3.4. Analysis by Target Therapeutic Area
4.3.5. Analysis by Kit Components
4.3.6. Analysis by Kit Wearability
4.3.7. Analysis by target analyte detection
4.3.8. Analysis by type of analyte acquisition method
4.3.9. Analysis by type of biofluid analyzed
4.3.10. Analysis by processing time
4.3.11. Analysis by number of regulatory approvals
4.3.12. Analysis by Kit Reusability
4.3.13. Analysis by availability of data management tools
4.3.14. Analysis by Follow-up Consultation Requirement
5. ALLOWANCE ANALYSIS
5.1. Chapter Overview
5.2. Scope and Methodology
5.3. Home self-test kits: Grant analysis
5.3.1. Analysis by Year of Grant Award
5.3.2. Analysis by Amount Awarded
5.3.3. Analysis by Support Period
5.3.4. Analysis by Support Period and Funding Institute Center
5.3.5. Analysis by type of grant application
5.3.6. Analysis by purpose of award
5.3.7. Analysis by activity code
5.3.8. Breakdown by NIH Spending Categories (Word Cloud Representation)
5.3.9. Analysis according to the relevant study section
5.3.10. Popular NIH Departments: Analysis by Number of Grants
5.3.11. Analysis by recipient organization type
5.3.12. Prominent Program Officers: Analysis by number of awards
5.3.13. Popular Recipient Organizations: Breakdown by number of awards
5.3.14. Popular Recipient Organizations: Breakdown by Amount Awarded
5.3.15. Analysis by Region of Recipient Organization
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key assumptions and parameters
6.3. Methodology
6.4. At-Home Self-Test Kit Developers: Company Competitiveness Analysis
6.4.1. Home Self Test Kits Developers based in North America
6.4.2. Home Self Test Kits Developers based in Europe
6.4.3. Home Self Test Kits Developers based in Asia Pacific
6.4.4. Home Self-Test Kits Developers: Competitive Benchmark
7. COMPANY PROFILE
7.1. Chapter Overview
7.2. ACON Laboratories
7.2.1. Product portfolio
7.2.2. Recent developments and future prospects
7.3. AdvaCare Pharma USA
7.3.1. Product portfolio
7.3.2. Recent developments and future prospects
7.4. Apex Biotechnology
7.4.1. Product portfolio
7.4.2. Recent developments and future prospects
7.5. i-SENS
7.5.1. Financial information
7.5.2. Product portfolio
7.5.3. Recent developments and future prospects
7.6. Oak Tree Health
7.6.1. Product portfolio
7.6.2. Recent developments and future prospects
7.7. TaiDoc Technology
7.7.1. Product portfolio
7.7.2. Recent developments and future prospects
7.8. VivaCheck Laboratories
7.8.1. Product portfolio
7.8.2. Recent developments and future prospects
8. BOWMAN CLOCK PRICING STRATEGY
8.1. Chapter Overview
8.2. Bowman Strategy Clock
8.2.1. Two dimensions of Bowman strategy clock
8.2.2. Eight positions on Bowman Strategy Clock
8.3. Roots Analysis Framework
8.3.1. Methodology
8.3.2. Theoretical Framework and Price Evaluation Hypothesis
8.3.3. Results and interpretation
8.3.3.1. Product Price Evaluation Matrix: Information on Type of Test Format
8.3.3.2. Product Price Evaluation Matrix: Information on the type of analyte acquisition method used
8.3.3.3. Product Price Evaluation Matrix: Information on type of biofluid analyzed
8.3.3.4. Product Price Evaluation Matrix: Information on number of regulatory approvals received
8.3.3.5. Product Price Evaluation Matrix: Information on Target Patient Population
8.3.3.6. Product Price Evaluation Matrix: Information on Availability of Data Management Tools
8.3.3.7. Product Price Evaluation Matrix: Information on target analyte detected
9. COMPARABLE COMPANY ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Operating statistics for comparable companies
9.4. Valuation statistics for comparable companies
9.5. Summary of Valuation for Abbott Laboratories
9.6. Summary of Valuation for Roche
9.7. Valuation Summary for Johnson & Johnson
10. LANDING
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Global demand for home self-test kits
10.4. Demand for home self-test kits: analysis by geography
10.5. Demand for home self-test kits: analysis by therapeutic area
10.6. Concluding remarks
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global market for home self-test kits, 2022-2035
11.4. Home Self-Test Kits Market: Analysis by Geography, 2022-2035
11.5. Home Self-Test Kits Market: Analysis by Therapeutic Area, 2022-2035
11.6. Home Self-Test Kits Market: Analysis by Test Format Type, 2022-2035
11.7. Home Self-Test Kits Market: Analysis by Type of Biofluid Analyzed, 2022-2035
12. ATTRACTIVENESS COMPETITIVENESS MATRIX
12.1. Chapter Overview
12.2. AC Matrix: Overview
12.2.1. Strong business segments
12.2.2. Average business segments
12.2.3. Weak business segments
12.3. Analytical Methodology
12.4. AC Matrix: Self-test kits at home in North America
12.5. AC Matrix: Self-test kits at home in Europe
12.6. AC Matrix: Self-test kits at home in Asia Pacific
13. CONCLUDING REMARKS
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Apex Biotechnology
14.2.1. Company screenshot
14.2.2. Interview Transcript: Ben Shen (Vice President, Sales and Marketing)
14.3. Mankind Pharma
14.3.1. Company screenshot
14.3.2. Interview Transcript: Joy Chatterjee (Associate Vice President)
15. APPENDIX I: TABULATED DATA
16. ANNEX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information on this report visit https://www.researchandmarkets.com/r/n1wjeo
English
French
Spanish